Noticias de PSTV_US

Noticias del mercado

Últimas noticias sobre PSTV_US — 164 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PSTV_US ✕ 164 resultados
31/03/2026 PSTV_US — Investing.com
Plus Therapeutics approves 1-for-25 reverse stock split
31/03/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
30/03/2026 PSTV_US — Stock Titan
PLUS THERAPEUTICS (PSTV) director files Form 3 with zero shares
26/03/2026 PSTV_US — Investing.com
Plus Therapeutics appoints Ron Andrews to board of directors
26/03/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Appoints Diagnostics and Molecular
26/03/2026 PSTV_US — Stock Titan
Veteran tied to $15B in exits joins Plus Therapeutics board
26/03/2026 PSTV_US — Yahoo Finance
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
26/03/2026 PSTV_US — GlobeNewswire ES ← EN
Plus Therapeutics designa diagnósticos y moleculares.
26/03/2026 PSTV_US — Stock Titan
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board
19/03/2026 PSTV_US — Yahoo Finance
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
19/03/2026 PSTV_US — Stock Titan
Late-stage LM care can top $100,000 a month, Plus analysis says
12/03/2026 PSTV_US — Yahoo Finance
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
12/03/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Reports 2025 Results, Business Progress
12/03/2026 PSTV_US — Stock Titan
Inside Plus Therapeutics' 2026 brain cancer drug and spinal fluid test plans
12/03/2026 PSTV_US — Yahoo Finance
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
12/03/2026 PSTV_US — GuruFocus
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline
12/03/2026 PSTV_US — TradingView
Plus Therapeutics 10-K: $5.21M Grant Revenue, Net Loss $0.29 EPS
12/03/2026 PSTV_US — GuruFocus
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline
25/02/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

Página 8 de 9

keyboard_arrow_up